dc.contributor.author | Lech, K | |
dc.contributor.author | Liu, F | |
dc.contributor.author | Davies, SK | |
dc.contributor.author | Ackermann, K | |
dc.contributor.author | Ang, JE | |
dc.contributor.author | Middleton, B | |
dc.contributor.author | Revell, VL | |
dc.contributor.author | Raynaud, FI | |
dc.contributor.author | Hoveijn, I | |
dc.contributor.author | Hut, RA | |
dc.contributor.author | Skene, DJ | |
dc.contributor.author | Kayser, M | |
dc.date.accessioned | 2017-09-19T08:32:14Z | |
dc.date.issued | 2018-01 | |
dc.identifier.citation | International journal of legal medicine, 2018, 132 (1), pp. 33 - ? | |
dc.identifier.issn | 0937-9827 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/830 | |
dc.identifier.eissn | 1437-1596 | |
dc.identifier.doi | 10.1007/s00414-017-1670-y | |
dc.format | Print | |
dc.format.extent | 33 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Erratum to: investigation of metabolites for estimating blood deposition time. | |
dc.type | Other | |
rioxxterms.versionofrecord | 10.1007/s00414-017-1670-y | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-01 | |
rioxxterms.type | Other | |
dc.relation.isPartOf | International journal of legal medicine | |
pubs.issue | 1 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) | |
pubs.publication-status | Published | |
pubs.volume | 132 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) | en_US |
dc.contributor.icrauthor | Raynaud, Florence | |